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Abstract
Objective The aim of this study was to evaluate the clini-
cal characteristics and survival outcomes of patients with
primary mediastinal germ cell tumor (PMGCT) by identify-
ing the prognostic factors and eYcacies of diVerent treat-
ment modalities.
Methods Fifty-Wve patients with PMGCT who were
treated consecutively at Cancer Center, Sun Yat-sen Uni-
versity, Guangzhou, from 1988 to 2010 were evaluated ret-
rospectively.
Results Fifty-two men and 3 women with a median age of
25 years were identiWed, of whom 17 (30.9%) had pure
seminomatous, 38 (69.1%) had nonseminomatous histol-
ogy, 27 (49.1%) had tumor located at mediastinum, 20
(36.4%) had lung metastases and/or eVusions, and 8
(14.5%) had distant metastases. Three treatments surgery,
chemotherapy, and radiotherapy were performed in 11
(20%) patients, two treatments chemotherapy plus surgery
or radiotherapy were performed in 25 (45.6%), and single
treatment surgery or chemotherapy was performed in 17
(30.9%). The other two patients (3.6%) received no treat-
ment. After a median follow-up time of 31.4 months, the 5-
year survival rate was 52%. The median overall survival
time was 87.9 months. Patients who received two treat-
ments had the longest survival time of 118.3 months,
P = 0.000. Those who had pure seminoma histology, whose
tumor conWned to the mediastinum and who achieved com-
plete or partial remission at initial evaluation, who had
complete resection and radiotherapy were considered to
have better prognosis according to univariate analysis. On
multivariate analysis, extension and response rate at initial
evaluation were independently predictive of survival.
Conclusions Primary mediastinal germ cell tumor is rare
with a dominant frequency in young male patients. Chemo-
therapy combined with local therapy like surgery or radio-
therapy is a reasonable treatment strategy recommended.
Extension and initial remission rate are independent prog-
nostic factors.
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Introduction
Primary mediastinal germ cell tumor is a rare subgroup of
germ cell tumors reported to account for less than 5% of
germ cell malignancies. It has similar clinical characteris-
tics and histopathologic distributions as its counterparts in
gonads (Moran et al. 1997a,  b), though diverse features
exist. Literatures reported that it is more common in men
than in women. In addition, it displays diVerent biological
behaviors in men than those originate in testis or in women
(Rodney et al. 2010, Schneider et al. 2004).
Histologically, it can be classically divided into two cate-
gories: seminomas and nonseminomatous. Each histological
subtype can be associated with another subtype that realizes a
so-called mixed germ cell tumor (Chetaille et al. 2010).
Patients with pure seminomatous histology in the medi-
astinum were reported to have chances of long-term cure of
almost 90%, but only 45% of patients with mediastinal
nonseminomas were estimated to be alive at 5 years, of
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whom outcomes were obviously worse than those in
gonads or retroperitoneal primary (Bokemeyer et al. 2002).
The most important attention is about the therapeutic
strategies. It was reported that cisplatin-based chemother-
apy regimens given to a maximum eVect followed by surgi-
cal consolidation resulted in long-term progression-free
survival and overall survival time, which was recom-
mended as the Wrst-line therapy. At relapse, earlier adminis-
tration of second-line chemotherapy established with a
basis on prognostic factors including staging system or
tumor markers status and so on may improve survival and
quality of life showed in several studies. High-dose chemo-
therapy supported by stem cell transplantation was also
attempted in patients with relapsed or refractory germ cell
tumor or who obtained partial remission after Wrst-line
treatment by researchers who indicated that an eVective
mean can be reached (Rodney et al. 2010; Schneider et al.
2000; Kang et al. 2008; Rick et al. 2004; Ishioka et al.
2010; Hara et al. 2006).
In literatures, histology (Takeda et al. 2003), extended
metastases, the number of metastatic sites (Bokemeyer
et al. 2001), surgical resection of the tumor, pathological
evidence of persistent viable tumor in resected remnants
(Rivera et al. 2010), elevated serum tumor markers after
operation (Kesler et al. 2008), and so on were considered to
be independent prognostic factors.
Owing to the rarity of the type of tumor, in recent
20 years, institutional publications on large numbers of
patients with primary mediastinal germ cell tumors are rare,
many of which are retrospective. No consensus of the treat-
ment strategies has been reached already. In order to get
more information of this type of tumor, with the ultimate
aim of improving the treatment eVect, we retrospectively
analyzed the patients with primary mediastinal germ cell
tumor visited at our hospital in recent years regarding the
clinicopathological characteristics and survival outcomes.
Materials and methods
Patients
From 1988 to 2010, 55 patients with primary mediastinal
germ cell tumor treated at Cancer Center, Sun Yat-sen Uni-
versity, Guangzhou, were identiWed, whose clinicopatho-
logical characteristics including age, sex, histology, disease
extent, tumor markers before treatment, treatment scenar-
ios, and initial response rate were retrospectively studied.
Follow-ups were done through telephone connection or
outpatient meeting in order to conWrm the survival status of
the patients. Fifty-two patients were referred at the initial
diagnosis. The other three patients were referred after the
surgical resection of the tumor elsewhere. Bulky masses
located at the mediastinum presented in all patients as chest
X-ray or CT scan showed before treatment. No clinical or
imaging detectable testicular or ovarian masses existed.
Histological diagnosis was made through core needle
biopsy or Wne-needle aspiration plus serum tumor markers
alpha-fetoprotein (AFP) or human chorionic gonadotropin
(beta-HCG) before therapy.
Treatment strategies
Triple-modality therapy including surgery followed by che-
motherapy and radiotherapy was performed in six patients,
and chemotherapy followed by surgery and radiotherapy was
performed in Wve patients. Twelve patients received chemo-
therapy plus radiotherapy. Seven patients received surgery
followed by chemotherapy. Five patients received chemo-
therapy followed by surgery. Chemotherapy alone was
oVered to 16 patients. Two patients underwent surgery alone.
Two patients did not receive any treatment owing to the poor
performance status. In 51 patients who have received chemo-
therapy, one to 14 courses of chemotherapy given at 3-week
intervals were provided, with the mean of 4.92 courses.
Initial chemotherapy regimens were included as follows:
doxorubicin plus vincristine plus bleomycin in two
patients, cyclophosphamide plus cisplatin plus doxorubicin
in Wve patients, cyclophosphamide plus etoposide plus cis-
platin in four patients, bleomycin plus etoposide plus cis-
platin in 30 patients, and etoposide plus ifosfamide plus
cisplatin in ten patients.
Response criteria
Complete resection was deWned as no macroscopic or
microscopic residual tumor. Incomplete resection was con-
sidered that evident macroscopic or microscopic residual
tumor existed. Initial evaluation was deWned as the
response rate evaluated after initial treatment including sur-
gery or two courses of chemotherapy. A complete response
(CR) was deWned as clinical or radiographic disappearance
of tumors and normalization of AFP and beta-HCG. A par-
tial response (PR) was deWned as residual imaging abnor-
malities with more than 50% decrease in either the primary
or metastatic sites and/or declining markers. Patients with
more than 25% increase in tumor size, new lesions or
increasing markers were considered as having progressive
disease (PD). Stable disease (SD) was deWned as neither
suYcient shrinkage to qualify for PR nor suYcient increase
to qualify for PD.
Statistical analysis
Follow-up time was deWned from the date of pathological
diagnosis to the date of death or last contact. A chi-squareJ Cancer Res Clin Oncol (2011) 137:1607–1612 1609
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test was used to compare the proportions of diVerent
groups. Survival time was estimated using life table method
and Kaplan–Meier method. The univariate inXuence of
each potential prognostic factor on overall survival was
analyzed by the log-rank test. Cox proportional hazard
model was used as multivariate analysis to investigate the
factors that had independent prognostic value. All data
analyses were performed using SPSS version 16.0. A
P < 0.05 was regarded as statistically signiWcant.
Results
Clinical Wndings
Primary mediastinal germ cell tumors occurred predomi-
nantly in young adults with a mean age of 24.65 years
(range, 12–64). Fifty-two men (94.5%) and 3 women
(5.5%) were identiWed. The age spectrum was diVerent
between men and women, with a mean age of 23.67 years
in men and 41.67 years in women. Seventeen (30.9%)
patients were diagnosed as having pure seminoma and 38
(69.1%) had nonseminomatous including embryonal carci-
noma, yolk-sac tumor, teratoma, and mixed nonseminomas.
Twenty-seven (49.1%) patients had tumors located at the
mediastinum, 20 (36.4%) had lung metastases and/or plural
or pericardial eVusion, and 8 (14.5%) had tumors metasta-
sized to distant sites.
At the time of diagnosis, 46 (83.6%) patients complained
of nonspeciWc symptoms, such as cough, chest pain, dysp-
nea, low fever, and apnea. Of 46 patients, 8 (14.5%) had
superior vena caval syndrome and 9 (16.4%) other patients
were asymptomatic whose tumors were found through rou-
tine health examination. A majority of patients were pre-
sented as enormous masses in the mediastinum encroaching
or compressing adjacent organs such as bronchus, heart,
and great vessels. Two patients had poor performance sta-
tus leading to the unavailability of treatment. The perfor-
mance status of others ranges from 0 to 2 (Table 1).
Treatment outcomes
Complete resection was available in 22 patients, whereas
incomplete resection was performed in seven patients,
including biopsy in four and hemisection in two. There was
no discrimination of complete resectability between
patients who had surgery as initial treatment (13 in 19) or
post-chemotherapy (9 in 10) (P = 0.367). Viable cells in the
post-excisional specimens were found in ten patients after
complete resection. The toxicities of chemotherapy were
tolerated. At initial evaluation, 13 (23.6%) patients
achieved CR, 18 (32.7%) achieved PR, 9 (16.4%) devel-
oped PD, and 13 (23.6%) remained stable.
Survival
With a median follow-up of 31.4 months (0.43–172.6
months), the 5-year survival time of the whole patient
group was 52%. The median overall survival time was
87.9 months. Patients who received two treatments had the
longest survival time of 118.3 months compared with those
received three (83.26 months), one (48.63 months) or no
treatment (4.65 months), P = 0.000. Five-year survival rate
of patients who had pure seminomatous histology was sta-
tistically better than that of those with nonseminomatous
(87% vs. 33%, P = 0.018). When categorized patients in
terms of disease extent, that is localized at the mediastinum,
metastasized to lungs and/or eVusions, or had metastases to
distant sites, diVerences in survival existed, 72%, 45%, zero
of three groups, respectively, P = 0.005. Furthermore,
patients who achieved CR or PR at initial evaluation (59,
70, 45, 0% for patients obtained CR, PR, SD, PD, respec-
tively, P = 0.000), or had neoplasms completely resected
(58, 29, 52% for completely resected, incompletely
resected, no resection, respectively, P = 0.028), and
received radiotherapy (60% vs. 43%, P = 0.008) were con-
sidered to have better prognosis according to univariate
analysis (Table 2; Figs. 1, 2).
Table 1 Characteristics of 55 patients with primary mediastinal germ
cell tumor
Characteristics No. of patients %
Age
·15 years 5 9.1
>15 years 50 90.9
Sex
Male 52 94.5
Female 3 4.5
Histopathology
Pure seminomatous 17 30.9
Teratoma 13 23.6
Embryonal 4 7.3
Yolk sac 2 3.6
Mixed nonseminomatous 18 32.7
Symptoms
Symptomatic 46 83.6
Asymptomatic 9 16.4
Superior vena caval syndrome 8 14.5
Disease extent
Circumscribed 27 49.1
Metastasizing to lung and/or eVusions 20 36.4
Metastasizing to distant places 8 14.5
Chemotherapy courses in 51 patients
1–4 courses 25 49
More than 4 courses 26 511610 J Cancer Res Clin Oncol (2011) 137:1607–1612
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Multivariate analysis
Potential prognostic factors were included in regression
models if there was statistical evidence of, or a theoretical
basis for, a relationship to overall survival. Two signiWcant
predictors of poor overall survival were identiWed: exten-
sive extent (P = 0.012) and poor response rate at initial
evaluation (P = 0.002). These factors were independently
predictive of lower probability of overall survival. The
association between overall survival and gender (P =
0.657), age at diagnosis (P = 0.59), histology (P =0 . 1 1 9 ) ,
chemotherapy courses (P = 0.248), and resectability (P = 0.59)
could not be established (Table 3).
Discussion
In this retrospective analysis of patients with primary medi-
astinal germ cell tumors, a predominant frequency of mor-
bidity in young adult patients was identiWed. The mean age
of the whole group was 24.65 years, of whom 50 were
older than 15 years. The peak of incidence was greater than
their counterparts in gonads contrasted historically. For
example, Dominik et al. reported 1,157 patients with germ
cell tumors in gonads of 1,442 patients were younger than
15 years in an epidemiological analysis (Schneider et al.
2004). Only 3 female patients with a mean age of
41.67 years were identiWed (sex ratio 17.3). This gender
and age tendencies were also reported by other studies
(Rivera et al. 2010; Nakamura et al. 2009).
At diagnosis, many patients complained of nonspeciWc
symptoms resembling common respiratory diseases, including
Table 2 The median overall survival time of patients with primary
mediastinal germ cell tumor according to diVerent characteristics
No. of patients OS (months) P
Sex 0.738
Males 52 92.04
Females 3 112.37
Histopathology 0.006
Pure seminomatous 17 148.99
Nonseminomatous 38 57.69
Extent of disease 0.002
Circumscribed 27 113.90
Lung metastases 
and/or eVusions
20 69.53
Distant metastases 8 14.33
Treatment scenarios 0.000
Three treatments 11 83.26
Two treatments 25 118.27
One treatments 17 48.63
No treatments 2 4.65
Resection 0.031
Complete 22 96.23
Incomplete 7 55.36
No resection 26 48.20
Radiotherapy 0.026
With 23 111.04
Without 32 66.56
Initial evaluation 0.000
CR + PR 31 106.46
SD 13 46.00
PD 11 10.87
Fig. 1 The survival curve of 55 patients with primary mediastinal
germ cell tumors
Fig. 2 The survival curves of patients with primary mediastinal germ
cell tumors with diVerent treatment strategiesJ Cancer Res Clin Oncol (2011) 137:1607–1612 1611
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cough, chest pain, dyspnea, low fever, and apnea. In addi-
tion, some patients were asymptomatic. It is one of the
causes leading to the postponing of diagnosis and treat-
ments. In the present study, more than half of the patients
have had tumors metastasized to lungs or distant sites
already at the time of visiting doctors. A statistically sig-
niWcant poorer survival of patients with extensive diseases
compared to those circumscribed was identiWed. Five-year
overall survival rate of patients who had tumors localized at
the mediastinum, metastasized to lungs or distant sites were
72%, 45%, and 0, respectively, P = 0.005. We obtained an
opinion which was agreed by previous experts that earlier
diagnosis and treatments are key strategies to improving the
therapeutic eYcacies and overall survival of patients with
primary mediastinal germ cell tumors (Moran et al. 1997c).
Imaging tests like chest X-ray and CT scan can be used
to displaying tumor lesions. A biopsy through Wne-needle
aspiration or mediastinoscopy plus tumor markers AFP and
beta-HCG are methods helping determine the histopatholo-
gical diagnosis. Gilligan et al. made a meta-analysis in
which serum tumor markers AFP or beta-HCG or lactate
dehydrogenase are recommended to be used to stage
patients or monitor for relapse in patients with nonsemino-
matous or advanced seminoma only, not to screen or decide
management strategies (Gilligan et al. 2010), we could not
make a deWnite recommendation for the use of biomarkers
owing to the deWcit of data.
Histology is an important prognostic factor indicating
the survival outcome of patients as elucidated by many lit-
eratures. In our study, we also found an evident discrimina-
tion of survival between patients with pure seminomatous
and nonseminomatous (5-year survival rate, 87 and 33%,
respectively, P = 0.018) despite no statistically signiWcant
diVerences according to the multivariate analysis.
With regard to the therapeutic strategies, previous
experts summarized their experiences including surgery,
chemotherapy, radiotherapy, and high-dose chemotherapy
with stem cell support, using small samples (Rodney et al.
2010; Kang et al. 2008; Bokemeyer et al. 2001; Lopes et al.
2009; Sakurai et al. 2004; Bokemeyer et al. 2003; Mann
et al. 2000). In this study, patients were categorized into
four groups: those who received three treatments surgery,
chemotherapy, and radiotherapy irrespective of the
sequence, those who received two treatments chemotherapy
plus surgery or radiotherapy, and those who received single
treatment chemotherapy or surgery. Another two patients
received no therapy. According to the result of log-rank
test, the patients who received two treatments had the lon-
gest survival time of 118.3 months. There were several rea-
sons. The superior and lasting toxicities of three treatments
are attributed to the worse survival, whereas single treat-
ment is incapable of eliminating the residual tumor or
micrometastases after chemotherapy or surgery due to the
extensive properties of germ cell tumors in the mediasti-
num. Two treatments chemotherapy plus local therapy sur-
gery or radiotherapy may be reasonable management
strategies recommended. But more explorations are
required to conWrm this.
Patients with primary mediastinal germ cell tumors were
classiWed as poor prognosis group according to IGCCC
(Mead and Stenning 1997). Several prognostic factors were
identiWed to better tailoring treatment. For example, Boke-
meyer et al. evaluated 635 patients with extragonadal germ
cell tumor over 21 years at 11 centers and concluded that
liver metastases and two or more metastatic sites inXuenced
survival negatively (Bokemeyer et al. 2001). In this study,
according to multivariate analysis, disease extension and
response rate at initial evaluation were independent prognos-
tic factors. We recommended that patients who did not reach
a complete or partial remission at initial evaluation should be
considered for more intensive therapies if tolerable.
However, due to the retrospective property and small
sample size of this study, much still remains to be done in
order to improving the survival of patients with PMGCT.
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